Conditions: Non-Squamous Non-Small Cell Lung Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 60
Healthy volunteers: no

Brief summary:
This open-label, single arm study will assess the correlation between Tarceva (erlotinib)-induced rash and efficacy in participants with inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC) receiving first-line therapy for advanced disease. Participants will receive Tarceva at a dose of 150 mg daily orally, with dose adjustments according to protocol depending on toxicity. Anticipated time on study treatment is until disease progression, unacceptable toxicity, or withdrawal due to any reason.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: erlotinib [Tarceva]
Intervention descriptions: intervention 1: 150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol

Protocol document: